Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. LoRusso · SciRah

Researcher profile · Semantic Scholar

P. LoRusso

Share profile

P. LoRusso — researcher profile on SciRah

h-index: 77
Works: 616
Citations: 30K

Most-cited papers

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Patients with Advanced Solid Tumors
K. Jung, P. LoRusso, H. Burris, M. Gordon +23 more
2019Clinical Cancer Research221 citations Open access
Semantic Scholar
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019
C. Price, F. Altice, Y. Shyr, Alan G. Koff +25 more
2020Chest171 citations Open access
Semantic Scholar
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
J. Atkins, G. George, K. Hess, Kathrina L. Marcelo-Lewis +5 more
2020British Journal of Cancer110 citations Open access
Semantic Scholar
Phase I trials as valid therapeutic options for patients with cancer
J. Adashek, P. LoRusso, D. Hong, R. Kurzrock
2019Nature Reviews Clinical Oncology109 citations Open access
Semantic Scholar
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
S. Piha-Paul, J. Sachdev, M. Barve, P. LoRusso +11 more
2019Clinical Cancer Research101 citations Open access
Semantic Scholar
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
A. Muik, E. Garralda, I. Altıntaş, F. Gieseke +34 more
2022Cancer Discovery99 citations Open access
Semantic Scholar
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
G. Shapiro, P. LoRusso, A. Dowlati, K. Do +14 more
2020British Journal of Cancer93 citations Open access
Semantic Scholar
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
G. Shapiro, P. LoRusso, E. Kwak, Susan S. Pandya +14 more
2019Investigational new drugs82 citations
Semantic Scholar
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.
M. Patel, T. Bauer, A. Jimeno, Ding Wang +14 more
202065 citations
Semantic Scholar
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
G. Falchook, S. Rosen, P. LoRusso, J. Watts +18 more
2019Clinical Cancer Research59 citations Open access
Semantic Scholar
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer
K. K. Budhraja, B. McDonald, M. D. Stephens, T. Contente-Cuomo +18 more
2023Science Translational Medicine50 citations Open access
Semantic Scholar
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
C. Weekes, A. C. Lockhart, P. LoRusso, Elaine Murray +8 more
2020The Oncologist46 citations Open access
Semantic Scholar
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
A. Naing, F. Thistlethwaite, E. D. de Vries, F. Eskens +14 more
2021Journal for ImmunoTherapy of Cancer43 citations Open access
Semantic Scholar
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
F. Janku, P. LoRusso, A. Mansfield, R. Nanda +5 more
2021Investigational new drugs42 citations
Semantic Scholar
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
M. Mita, P. LoRusso, K. Papadopoulos, M. Gordon +7 more
2020Clinical Cancer Research37 citations
Semantic Scholar
Improved methods for RNAseq-based alternative splicing analysis
R. Halperin, A. Hegde, Jessica D. Lang, Elizabeth A. Raupach +9 more
2021Scientific Reports36 citations Open access
Semantic Scholar
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W. Kim, R. McKay, M. Radke, Shi-Lin Zhao +20 more
2022Journal of Clinical Oncology35 citations Open access
Semantic Scholar
A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance.
T. Yap, P. LoRusso, D. Wong, S. Hu-Lieskovan +18 more
2022Clinical Cancer Research33 citations Open access
Semantic Scholar
Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
E. R. Roussos Torres, C. Rafie, Chenguang Wang, David Lim +17 more
2021Clinical Cancer Research30 citations Open access
Semantic Scholar
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
F. Atrafi, O. Boix, V. Subbiah, J. Diamond +13 more
2021Clinical Cancer Research28 citations Open access
Semantic Scholar
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
G. Shapiro, P. LoRusso, D. Cho, L. Musib +8 more
2020Investigational new drugs27 citations
Semantic Scholar
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
M. Abidi, D. Aboulafia, M. Accordino, J. Acoba +278 more
2020Cancer Cell26 citations Open access
Semantic Scholar
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
S. Sandhu, C. McNeil, P. LoRusso, M. Patel +12 more
2019Investigational new drugs26 citations
Semantic Scholar
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
A. Naing, J. Infante, S. Goel, H. Burris +17 more
2019Journal of Immunotherapy for Cancer26 citations Open access
Semantic Scholar
A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
A. Tolcher, B. Carneiro, A. Dowlati, A. A. Abdul Razak +10 more
202125 citations
Semantic Scholar
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
K. Bible, M. Menefee, Chia-Chi Lin, M. Millward +23 more
2020Thyroid25 citations Open access
Semantic Scholar
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
P. LoRusso, M. Ratain, T. Doi, D. Rasco +13 more
2022Investigational new drugs24 citations Open access
Semantic Scholar
Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors
F. Braiteh, P. LoRusso, A. Balmanoukian, S. Klempner +17 more
2020Tumor Biology24 citations
Semantic Scholar
Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
J. Bendell, P. Bedard, Y. Bang, P. LoRusso +30 more
2020Bioinformatics, Convergence Science, and Systems Biology22 citations
Semantic Scholar
Improving attribution of adverse events in oncology clinical trials.
G. George, Pedro C. Barata, A. Campbell, Alice Chen +22 more
2019Cancer Treatment Reviews22 citations
Semantic Scholar
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
J. Strickler, P. LoRusso, R. Salgia, Yoon-Koo Kang +11 more
2020Molecular Cancer Therapeutics19 citations Open access
Semantic Scholar
Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.
M. Ratain, T. Doi, M. D. de Jonge, P. LoRusso +7 more
2019Journal of Clinical Oncology19 citations
Semantic Scholar
Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
M. Gounder, T. Bauer, G. Schwartz, P. LoRusso +6 more
202018 citations Open access
Semantic Scholar
Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
J. Sachdev, T. Bauer, S. Chawla, S. Pant +8 more
2019Journal of Clinical Oncology18 citations
Semantic Scholar
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
A. Naing, J. Powderly, J. Nemunaitis, J. Luke +10 more
2022Journal for ImmunoTherapy of Cancer17 citations Open access
Semantic Scholar
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
L. Chow, J. Gainor, N. Lakhani, Keun-Wook Lee +14 more
202017 citations
Semantic Scholar
One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable.
P. LoRusso, J. Sebolt-Leopold
2020New England Journal of Medicine16 citations
Semantic Scholar
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W. Kim, D. Cardin, U. Vaishampayan, S. Kato +5 more
2021The Oncologist15 citations Open access
Semantic Scholar
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach
K. Ogasawara, P. LoRusso, A. Olszanski, O. Rixe +4 more
2020Cancer Chemotherapy and Pharmacology12 citations
Semantic Scholar
Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry
X. Bao, Jian-Mei Wu, B. Shuch, P. LoRusso +2 more
2019Scientific Reports12 citations Open access
Semantic Scholar
CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
A. Naing, F. Thistlethwaite, A. Spira, J. García-Corbacho +12 more
2019Journal of Clinical Oncology12 citations
Semantic Scholar
Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission.
R. Casolino, J. Mateo, E. D. de Vries, A. Johns +52 more
2026The Lancet Oncology11 citations Open access
Semantic Scholar
Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.
C. Muller, U. Brown-Glaberman, M. Chaney, T. Garyantes +10 more
202111 citations
Semantic Scholar
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
T. Yap, L. Siu, E. Calvo, M. Lolkema +6 more
2021The Lancet Oncology11 citations Open access
Semantic Scholar
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
V. Boni, H. Burris, Joyce F. Liu, A. Spira +16 more
202011 citations
Semantic Scholar
395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy
T. Yap, D. Wong, S. Hu-Lieskovan, K. Papadopoulos +5 more
202011 citations Open access
Semantic Scholar
A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
J. Shaya, Wan-Ling Xie, B. Saraiya, M. Parikh +12 more
2021Journal of Clinical Oncology10 citations
Semantic Scholar
Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).
Joseph W. Kim, M. Milowsky, N. Hahn, D. Kwiatkowski +11 more
202110 citations
Semantic Scholar
Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells
Isabel Alvarado-Cruz, M. Mahmoud, Mohammed Khan, Shi-Lin Zhao +16 more
2020Biochemical Pharmacology10 citations Open access
Semantic Scholar
FPA150 (B7-H4 antibody) phase I update in advanced solid tumours: Monotherapy and in combination with pembrolizumab
Z. Wainberg, J. Sachdev, T. Bauer, S. Pant +7 more
2019Annals of Oncology10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Calvo×6
Invite
E. Calvo — researcher profile on SciRah
Y. Shyr×6
Invite
Y. Shyr — researcher profile on SciRah
G. Shapiro×6
Invite
G. Shapiro — researcher profile on SciRah
J. Bendell×5
Invite
J. Bendell — researcher profile on SciRah

×4

Invite

M. Gordon — researcher profile on SciRah

Invite

D. Hong — researcher profile on SciRah

Invite

J. Eder — researcher profile on SciRah

Invite

T. Bauer — researcher profile on SciRah

Invite

A. Naing — researcher profile on SciRah

Invite

A. Spira — researcher profile on SciRah

K. Papadopoulos×4

Invite

K. Papadopoulos — researcher profile on SciRah

Invite

T. Yap — researcher profile on SciRah